Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 9,204 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: no treatment Clear all
Completed Phase 3 Interventional

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

NCT00003934
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3), Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
tretinoin, daunorubicin hydrochloride, cytarabine, mercaptopurine, methotrexate, arsenic trioxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional Results available

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

NCT01367834
View directory record Official record
Conditions
Turner Syndrome
Interventions
somatotropin
Drug
Lead sponsor
Rebecca Knickmeyer Santelli, PhD
Other
Eligibility
11 Months to 13 Months · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 1, 2026, 9:45 AM EDT
Terminated Phase 1 Interventional

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

NCT03126864
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, CD33-CAR-T Cell Infusion
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 1, 2026, 9:45 AM EDT
Completed No phase listed Observational

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

NCT05096039
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,614,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults

NCT01489930
View directory record Official record
Conditions
Sarcopenia
Interventions
Endurance exercise, Resistance exercise, Control/Combined training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lactobacillus Probiotic for Prevention of UTI

NCT03151967
View directory record Official record
Conditions
Urinary Tract Infections (UTI's)
Interventions
Lactobacillus crispatus CTV-05, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 3 Interventional Results available

Antibiotic Study for Dental Implants

NCT00662532
View directory record Official record
Conditions
Periodontitis
Interventions
Minocycline HCl
Drug
Lead sponsor
OraPharma
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Hazlet, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 1, 2026, 9:45 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents

NCT03338751
View directory record Official record
Conditions
Hearing Impairment
Interventions
cognitive testing with HAD (PockeTalker) First, Cognitive testing without HAD First
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 1, 2026, 9:45 AM EDT
Recruiting Not applicable Interventional

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

NCT07051707
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Targeted Lung Denervation (TLD)
Device
Lead sponsor
Nuvaira, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Jacksonville, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 1, 2026, 9:45 AM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 1, 2026, 9:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT05371964
View directory record Official record
Conditions
Myelofibrosis
Interventions
Imetelstat sodium, Ruxolitinib
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 9:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Young Adult Smoker's Treatment Demand

NCT01569529
View directory record Official record
Conditions
Smoking Cessation
Interventions
Online advertisement
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 30 Years
Enrollment
3,070 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

NCT02176031
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Natalizumab, Methylprednisolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Therapy in Addition to Standard Care Following C-Section

NCT02804139
View directory record Official record
Conditions
Low Back Pain, Pelvic Pain, Scar Tissue, Adhesions
Interventions
Standard care plus physical therapy, Standard Care
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

NCT00003207
View directory record Official record
Conditions
Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pegylated liposomal doxorubicin hydrochloride, PSC 833
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 1, 2026, 9:45 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

NCT00985036
View directory record Official record
Conditions
Glioma, Meningioma
Interventions
Blood test
Procedure
Lead sponsor
Marquette General Health System
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Marquette, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 1, 2026, 9:45 AM EDT
Terminated No phase listed Observational

Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture

NCT00643175
View directory record Official record
Conditions
Osteoporosis
Interventions
Automated follow up
Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The UNCODE Study: Unravelling the Neural Contributors Of Dynapenia in Elders

NCT02505529
View directory record Official record
Conditions
Aging
Interventions
Resistance Exercise Training, Mental Imagery
Other
Lead sponsor
Ohio University
Other
Eligibility
60 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

NCT03463837
View directory record Official record
Conditions
Nicotine Dependence, Other Tobacco Product, Tobacco Use, Smoking, Tobacco
Interventions
Treatment with JUUL 5%, Virginia Tobacco, Treatment with JUUL 5%, Cool Mint, ENDS, Treatment with JUUL 5%, Mango, ENDS, JUUL 5%, Creme Bruele, ENDS, Combustible cigarette, Smoking Cessation
Other
Lead sponsor
Juul Labs, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anxiety and Recurrent Abdominal Pain in Children

NCT00962039
View directory record Official record
Conditions
Abdominal Pain, Anxiety
Interventions
Citalopram, Placebo
Drug
Lead sponsor
John V. Campo, M.D.
Other
Eligibility
7 Years to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Not applicable Interventional

Intermittent Pneumatic Compression With and Without Exercise to Improve Functioning in Peripheral Artery Disease

NCT03871075
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
intermittent pneumatic compression, exercise, Sham device, Health Education
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Detroit, Michigan • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 1, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 1, 2026, 9:45 AM EDT
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 1, 2026, 9:45 AM EDT